A New Technology for Blood Conservation using Hemoconcentration A Universal Blood Reservoir for Salvaging Autologous Whole Blood from any ECC. The Hemobag ® is specifically designed for Filling, Hemoconcentrating and Infusing Blood Quickly all in the same device, and will double the use of any commercially available Hemoconcentrator. It even keeps the ECC circuit primed at all times for piece of mind and security.

Hemobag ® Case Series Salem Hospital, Salem OR HB vs. NHB group comparison:  No significant difference in distribution of surgeons, procedures, patient age, BSA or gender between groups  No significant difference in CPB and ischemic (clamp) times between groups  No significant difference in National Bayes Risk Scores but the Hemobag ® Pts. trended to Higher Risk Scores  HB group cooled to a significantly (p = 0.45) lower temperature (30.6 o C) than control group (32.9 o C)  Same volume of pre-CPB autologous blood drawn (ANH)  Same 100% use of cell-processor in both groups except the use of the HemoBag ® to process the end-CPB circuit volume in the HB group

Hemobag ® Case Series Salem Hospital, Salem OR Methodology  The end-CPB circuit blood for a group of 41 patients was processed using the Hemobag ® (HB) device and technique  HB procedures and patients were selected randomly from all comers in community-based medical center  A retrospective, matched patient group (non-HemoBag ®, NHB) was selected to compare to the Hemobag ® patient group  The control group patients were selected to match the HB group patients by procedure, surgeon, CPB time, Clamp time, age and BSA  The control group end-CPB circuit blood was processed by the Cell Saver ®  Compared pre-op, operative, ICU and post-op parameters, outcomes and blood product usage and cost between HB and NHB groups

Hemobag ® Case Series Salem Hospital, Salem OR HB vs. NHB group comparison:  There was no difference in operative hematocrit nadir, post-op HCT or chest tube drainage volume  Though not statistically significant at group sizes (n= 41), the differences were clinically relevant, and had sizeable financial consequences:  Hemobag ® patients received 1/3 less total donor exposures on the average compared to control group  Average RBC transfusion rates per patient were lower (>50%) in the HB group (p = 0.081) compared to the control patients  Hemobag ® patients blood costs were about 50% of control group blood costs per patient (p = 0.134)

More patients received no blood products in HemoBag ® group  49% of the HemoBag ® patients received no blood products compared to 34% of the control group patients 49 % 34 %

Total cost of blood products was reduced in the HemoBag ® group  All blood products for the 41 HemoBag ® patients cost about $27,631 versus $50,564 for the 41 control group patients.  A Difference of $23,933 was realized in the 41 Patients in the Hemobag ® group.

Results represent what is possible with the Hemobag ® FLAGSHIP CASE #1: FLAGSHIP CASE #1: Over 80y/o female, AVR case, post-op bleeding: 300mL, left ICU post-op Day #1, no blood products given 900 mL Conc. Autologous Whole BloodReinfused 900 mL Conc. Autologous Whole Blood from CPB circuit with: –Hct = 57% –Platelets = 364 K –Fibrinogen = 740 mg –Albumin = 6.6 g/dL –Total protein = 11.7 g/dL Time: 12 minutes Extracorporeal circuit kept viable & ready to go back emergently

FLAGSHIP CASE #2: FLAGSHIP CASE #2: 60 yr old CABG x 3, post-op bleeding was 290 mL, left ICU on Post-op Day #1, no blood products given 1150 mL Conc. Autologous Whole BloodReinfused 1150 mL Conc. Autologous Whole Blood from CPB circuit with: –Hct = 56% –Platelets = 430 K –Fibrinogen = 972 mg –Albumin = 5.7 g/dL –Total protein = 13.6 g/dL –300% increase in FVII 73% activity to 223% Time: 10 minutes Extracorporeal circuit kept viable & ready to go back Illustrates capabilities of the Hemobag ® when used for Whole Blood Salvaging in CV Surgery